Nebenwirkungen · Veklury
Veklury 100 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 8
HOS-148236 · Präparat HOS-099858
Table 7: Tabulated list of adverse reactions Frequency Adverse reaction Immune system disorders Rare hypersensitivity Not known anaphylactic reaction, anaphylactic shock Nervous system disorders Common headache Cardiac disorders Not known sinus bradycardia* Gastrointestinal disorders Common nausea Hepatobiliary disorders Very common transaminases increased Skin and subcutaneous tissue disorders Common rash Investigations Very common prothrombin time prolonged Injury, poisoning and procedural complications Rare infusion-related reaction *Reported in post-marketing, usually normalised within 4 days following last remdesivir administration without additional intervention
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-06T14:35:00Z · SHA-256 62bbcc5dde40e3d37fece6b0e45bdeb958676b6cca0903934c50ff2a8f5a02f8 · Passage 236750829435027cdedb0653dbeef25ee3a623e58cc91653166b476083d5a52c · Zeichen 532–1429 im Abschnitt